Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | APLNR | P35414 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28414501 | 0.91 | CA12 (0.43) | CA12CA7CA14CA1APLNR | |
| SCHEMBL28410020 | 0.91 | CA12 (0.48) | CA12CA7CA14CA1APLNR | |
| SCHEMBL28413065 | 0.89 | CA12 (0.52) | CA12CA7CA14CA1APLNR | |
| SCHEMBL21806108 | 0.80 | — | — | |
| SCHEMBL24773688 | 0.79 | CA12 (0.55) | CA12CA7CA14CA1CA2 | |
| SCHEMBL16364952 | 0.79 | GABRA1 (0.48) | CA12CA7CA14CA1CA2 | |
| SCHEMBL12970652 | 0.75 | CA12 (0.50) | CA12CA7CA14CA1CA2 | |
| SCHEMBL27994463 | 0.74 | GABRA1 (0.43) | CA12CA7CA14CA1CA2 | |
| Hydrochloric Acid SCHEMBL13386291 | 0.73 | LMNA (0.41) | CA12CA7CA14CA1CA2 | |
| SCHEMBL13580239 | 0.71 | KCNH2 (0.41) | CA12CA7CA14APLNRJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103524393-B | Azetidine-3-sulfanilamide derivative and synthetic method thereof | GUANGDONG HOSPITAL TRADITIONAL CHINESE MEDICINE | 2015-01-07 | — | — | CN | claimed |
| CN-103524393-A | Azetidine-3-sulfanilamide derivative and synthetic method thereof | GUANGDONG HOSPITAL TRADITIONAL CHINESE MEDICINE | 2014-01-22 | — | — | CN | claimed |
| EP-3548495-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2021-01-27 | — | — | EP | disclosed |
| CN-110914256-A | Novel sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-3548495-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10100058-B2 | Fused heterocyclic compounds as CaM kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| WO-2018102384-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-05-31 | — | — | US | disclosed |
| CN-103524393-B | Azetidine-3-sulfanilamide derivative and synthetic method thereof | GUANGDONG HOSPITAL TRADITIONAL CHINESE MEDICINE | 2015-01-07 | — | — | CN | disclosed |
| CN-103524393-A | Azetidine-3-sulfanilamide derivative and synthetic method thereof | GUANGDONG HOSPITAL TRADITIONAL CHINESE MEDICINE | 2014-01-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10100058-B2 | Fused heterocyclic compounds as CaM kinase inhibitors | CAMK1, CAMKK1, CAMK1D | CA12 2073/4885CA7 1379/4885CA14 2817/4885 |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | CAMK1, CAMKK1, CAMK1D | CA12 2073/4885CA7 1379/4885CA14 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.